pubmed.ncbi.nlm.nih.gov

Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010 - PubMed

Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010

Marcus A Bachhuber et al. JAMA Intern Med. 2014 Oct.

Erratum in

  • JAMA Intern Med. 2014 Nov;174(11):1875

Abstract

Importance: Opioid analgesic overdose mortality continues to rise in the United States, driven by increases in prescribing for chronic pain. Because chronic pain is a major indication for medical cannabis, laws that establish access to medical cannabis may change overdose mortality related to opioid analgesics in states that have enacted them.

Objective: To determine the association between the presence of state medical cannabis laws and opioid analgesic overdose mortality.

Design, setting, and participants: A time-series analysis was conducted of medical cannabis laws and state-level death certificate data in the United States from 1999 to 2010; all 50 states were included.

Exposures: Presence of a law establishing a medical cannabis program in the state.

Main outcomes and measures: Age-adjusted opioid analgesic overdose death rate per 100 000 population in each state. Regression models were developed including state and year fixed effects, the presence of 3 different policies regarding opioid analgesics, and the state-specific unemployment rate.

Results: Three states (California, Oregon, and Washington) had medical cannabis laws effective prior to 1999. Ten states (Alaska, Colorado, Hawaii, Maine, Michigan, Montana, Nevada, New Mexico, Rhode Island, and Vermont) enacted medical cannabis laws between 1999 and 2010. States with medical cannabis laws had a 24.8% lower mean annual opioid overdose mortality rate (95% CI, -37.5% to -9.5%; P = .003) compared with states without medical cannabis laws. Examination of the association between medical cannabis laws and opioid analgesic overdose mortality in each year after implementation of the law showed that such laws were associated with a lower rate of overdose mortality that generally strengthened over time: year 1 (-19.9%; 95% CI, -30.6% to -7.7%; P = .002), year 2 (-25.2%; 95% CI, -40.6% to -5.9%; P = .01), year 3 (-23.6%; 95% CI, -41.1% to -1.0%; P = .04), year 4 (-20.2%; 95% CI, -33.6% to -4.0%; P = .02), year 5 (-33.7%; 95% CI, -50.9% to -10.4%; P = .008), and year 6 (-33.3%; 95% CI, -44.7% to -19.6%; P < .001). In secondary analyses, the findings remained similar.

Conclusions and relevance: Medical cannabis laws are associated with significantly lower state-level opioid overdose mortality rates. Further investigation is required to determine how medical cannabis laws may interact with policies aimed at preventing opioid analgesic overdose.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Cunningham’s husband was recently employed by Pfizer Pharmaceuticals and is currently employed by Quest Diagnostics. No other disclosures are reported.

Figures

Figure 1
Figure 1. Mean Age-Adjusted Opioid Analgesic Overdose Death Rate

States with medical cannabis laws compared with states without such laws in the United States, 1999–2010.

Figure 2
Figure 2. Association Between Medical Cannabis Laws and Opioid Analgesic Overdose Mortality in Each Year After Implementation of Laws in the United States, 1999–2010

Point estimate of the mean difference in the opioid analgesic overdose mortality rate in states with medical cannabis laws compared with states without such laws; whiskers indicate 95% CIs.

Comment in

Similar articles

Cited by

References

    1. Gaskin DJ, Richard P. The economic costs of pain in the United States. J Pain. 2012;13(8):715–724. - PubMed
    1. Daubresse M, Chang HY, Yu Y, et al. Ambulatory diagnosis and treatment of nonmalignant pain in the United States, 2000–2010. Med Care. 2013;51 (10):870–878. - PMC - PubMed
    1. Centers for Disease Control and Prevention. Vital signs: overdoses of prescription opioid pain relievers—United States, 1999–2008. MMWR Morb Mortal Wkly Rep. 2011;60(43):1487–1492. - PubMed
    1. Jones CM, Mack KA, Paulozzi LJ. Pharmaceutical overdose deaths, United States, 2010. JAMA. 2013;309(7):657–659. - PubMed
    1. National Center for Injury Prevention and Control Division of Unintentional Injury Prevention. [Accessed January 27, 2014];Policy impact: prescription painkiller overdoses. http://www.cdc.gov/homeandrecreationalsafety/pdf/policyimpact-prescripti.... Published November 2011.

Publication types

MeSH terms

Substances